Crystalline form of pemetrexed disodium
AssigneesAzad Pharmaceutical Ingredients AG, University of Zurich
InventorsUwe Jens Albrecht, Hannes Helmboldt, Vsevolod Valerievich Nikolaev
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new polymorphic or crystalline form of Pemetrexed Disodium, processes for its preparation and its use, in particular for the preparation of medicaments.
Claims33
Crystalline form of Pemetrexed Disodium which has characteristic reflexes in an X-ray powder diffractogram using CuKα radiation with Cukβ filter at a 2θ angle:
- 7.7±0.2, 9.7±0.2, 18.6±0.2, 19.2±0.2, 20.4±0.2, 24.3±0.2, 26.6±0.2, 28.7±0.2, 28.9±0.2, and 30.0±0.2.
A method for inhibiting, the folate metabolic pathway, thymidylate synthase, dihydrofolate reductase and/or glycinamide ribonucleotide formyl transferase, comprising administering to a patient in need of such treatment, a crystalline form of Pemetrexed Disodium which has a property of characteristic reflexes in an X-ray powder diffractogram using CuKα radiation with Cukβ filter at a 2θ angle:
- 7.7±0.2, 9.7±0.2, 18.6±0.2, 19.2±0.2, 20.4±0.2, 24.3±0.2, 26.6±0.2, 28.7±0.2, 28.9±0.2, and 30.0±0.2.
Dependencies are inferred from the claim text.